# A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

> **NCT03517488** · PHASE1 · COMPLETED · sponsor: **Xencor, Inc.** · enrollment: 150 (actual)

## Conditions studied

- Melanoma
- Breast Carcinoma
- Hepatocellular Carcinoma
- Urothelial Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Non-small Cell Lung Carcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Endometrial Carcinoma
- Mesothelioma
- Neuroendocrine Carcinoma
- Cervical Cancer
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of the Anus
- Castration-Resistant Prostate Carcinoma
- Nasopharyngeal Carcinoma
- Cholangiocarcinoma
- Basal Cell Carcinoma
- Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Thymoma
- Thymic Carcinoma
- Squamous Cell Carcinoma of the Penis
- Vulvar Carcinoma
- Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
- Malignant Adnexal Neoplasms
- Non-squamous Cell Salivary Gland Carcinoma

## Interventions

- **BIOLOGICAL:** XmAb20717

## Key facts

- **NCT ID:** NCT03517488
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-10
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-09-06
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03517488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03517488, "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03517488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*